NASDAQ:KALA
KALA BIO, Inc.
KALA BIO, Inc.'s revenue was $0 in fiscal 2025. The diluted share count rose 114.7%.Summary generated from KALA BIO, Inc.'s SEC filings. Latest annual report filed Apr 15, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−279.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+114.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 11 | 4 | 0 | 0 | 0 |
| Operating income | −130 | −82 | −40 | −41 | −39 |
| Net income | −143 | −45 | −42 | −39 | −27 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- DEF 14AProxy statement
Sep 24, 2026 - 8-KEntry into a material agreement
Sep 10, 2026 - 8-KOther events
Sep 9, 2026 - 8-KNotice of delisting or listing-rule failure
Aug 28, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 19, 2026 - 8-KOther events
Jul 23, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026 - 8-KAmendment to articles or bylaws
May 7, 2026